株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

高血圧治療薬の世界市場:2016〜2020年

Global Hypertension Drugs Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 299263
出版日 ページ情報 英文 87 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
高血圧治療薬の世界市場:2016〜2020年 Global Hypertension Drugs Market 2016-2020
出版日: 2016年04月13日 ページ情報: 英文 87 Pages
概要

世界の高血圧治療薬市場は、2016〜2020年にかけ、CAGR0.93%で拡大すると予測されています。高血圧は血管の内壁に対する過度の圧力がかかるもので、肺動脈高血圧と全身性高血圧に分類されます。

当レポートでは、世界の高血圧治療薬市場の現状と2020年までの成長見通し、市場の動向と課題、地域別動向、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 心血管薬剤市場

  • 世界の医薬品市場
  • 世界の心血管薬剤市場

第6章 概要:高血圧

  • 全身性高血圧
  • 肺動脈高血圧

第7章 疫学および経済的負担

第8章 パイプラインポートフォリオ

第9章 市況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第10章 タイプ場セグメンテーション

  • 全身性高血圧薬剤市場
  • 肺動脈高血圧薬剤市場

第11章 薬剤クラス別市場セグメンテーション

第12章 地域別セグメンテーション

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第13章 市場促進因子

第14章 促進因子の影響

第15章 市場の課題

第16章 促進因子と課題の影響

第17章 市場動向

第18章 ベンダー環境

  • 競合シナリオ
  • 市場シェア分析:2015年
  • Novartis
  • 第一三共株式会社
  • Actelion Pharmaceuticals
  • Boehringer Ingelheim
  • Sanofi
  • AstraZeneca
  • その他の注目すべきベンダー

第19章 付録

第20章 Technavioについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR9233

About Hypertension Drugs

Hypertension, or high blood pressure (BP), develops when there is too much pressure against the inner walls of blood vessels. Depending on the pressure exerted, hypertension can be classified as:

  • PAH
  • Systemic hypertension (commonly referred to as hypertension)

PAH, high BP in the arteries that carry blood from the heart to the lungs, occurs when blood vessels narrow, making blood flow difficult. This creates pressure on the heart's right ventricle, which increases in size and becomes weaker due to the excess load, leading to heart failure. The normal pulmonary arterial pressure at rest is 14 mmHg and increases from 25 mmHg to 30 mmHg.

Systemic hypertension occurs when blood vessels that supply oxygenated blood to the body become narrower, creating pressure on the right side of the heart. Hypertension can lead to damaged organs and illnesses such as renal failure (kidney failure), aneurysm, heart failure, stroke, or heart attack. Hypertension is classified into two types:

  • Primary or essential hypertension: It is defined as high BP with no known cause, and includes around 90%-95% of all hypertension cases
  • Secondary hypertension: It is high BP with a known direct cause, including kidney disease, tumors, or birth control pills, and includes 5%-10% of all hypertension cases

Technavio's analysts forecast the global hypertension drugs market to decline at a CAGR of (0.93) % during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypertension drugs market for 201652020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent hypertension and pulmonary arterial hypertension (PAH).

The market is divided into the following segments based on geography:

  • Americas
  • EMEA
  • APAC

Technavio's report, Global Hypertension Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Actelion Ltd.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company, Ltd.
  • Novartis AG
  • Sanofi SA

Other Prominent Vendors

  • Actelion Pharmaceuticals
  • Arena Pharmaceuticals
  • Asahi Kasei
  • Bayer HealthCare
  • Bellerophon Therapeutics
  • Bial
  • CJ HealthCare
  • Conatus Pharmaceuticals
  • Daiichi Sankyo
  • Deka Pharmaceuticals
  • Dong-A ST
  • Eiger BioPharmaceuticals
  • Forest Laboratories
  • Gilead Sciences
  • HanAll BioPharma
  • Hanmi Pharmaceutical
  • Johnson & Johnson
  • LG Life Sciences
  • Lung Biotechnology
  • Lupin Pharmaceuticals
  • Mast Therapeutics
  • Merck
  • Northern Therapeutics
  • Ono Pharmaceutical
  • Pfizer
  • PhaseBio
  • Pluristem Therapeutics
  • Quantum Genomics
  • Radikal Therapeutics
  • Reata Pharmaceuticals
  • Serodus
  • sigma-tau i.f.r
  • SteadyMed Therapeutics
  • Suda
  • Sun Pharmaceutical Industries
  • Symplmed Pharmaceuticals
  • Takeda Pharmaceuticals
  • United Therapeutics
  • Valeant Pharmaceuticals
  • XOMA
  • Yuhan

Market driver

  • Growing older population
  • For a full, detailed list, view our report

Market challenge

  • Patent expiries of major drugs
  • For a full, detailed list, view our report

Market trend

  • Increase in awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Cardiovascular drugs market

  • Global pharmaceuticals market
  • Global cardiovascular drugs market

PART 06: Overview: Hypertension

  • Systemic hypertension
  • PAH

PART 07: Epidemiology and economic burden

  • Economic burden

PART 08: Pipeline portfolio

PART 09: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 10: Market segmentation by type

  • Global systemic hypertension drugs market
  • Global PAH drugs market

PART 11: Market segmentation by drug class

  • Systemic hypertension
  • PAH

PART 12: Geographical segmentation

  • Global hypertension drugs market by geographical segmentation 2015-2020
  • Hypertension drugs market in Americas
  • Hypertension drugs market in EMEA
  • Hypertension drugs market in APAC

PART 13: Market drivers

  • Growing older population
  • Rise in sedentary lifestyle
  • High prevalence of chronic conditions
  • Patient assistance programs

PART 14: Impact of drivers

PART 15: Market challenges

  • Patent expiries of major drugs
  • Adverse effects
  • Poor patient compliance
  • Availability of alternative therapies

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Increase in awareness
  • Increased focus on combination therapies
  • Intense competition among vendors
  • Strategic alliances

PART 18: Vendor landscape

  • Competitive scenario
  • Market share 2015
  • Novartis
  • Daiichi Sankyo
  • Actelion Pharmaceuticals
  • Boehringer Ingelheim
  • Sanofi
  • AstraZeneca
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for drugs that treat hypertension
  • Exhibit 03: Patent expiries of major cardiovascular drugs
  • Exhibit 04: Global cardiovascular drugs market by generic and branded drugs sales 2015
  • Exhibit 05: Top 10 companies in global cardiovascular drugs market 2014
  • Exhibit 06: Pathophysiology of hypertension
  • Exhibit 07: Treatment algorithm for hypertension
  • Exhibit 08: Prevalence of PAH by cause
  • Exhibit 09: Projected prevalence of CVDs in US 2010-2030 (% of population)
  • Exhibit 10: Prevalence of hypertension in US population 2010-2030 (% of population)
  • Exhibit 11: Projected direct and indirect burden of hypertension in US 2010-2030 ($ billions)
  • Exhibit 12: Projected mortality trend for CVDs globally 2015 and 2030
  • Exhibit 13: Pipeline portfolio: Global systemic hypertension drugs
  • Exhibit 14: Pipeline portfolio: Global PAH drugs
  • Exhibit 15: Market share of global hypertension drugs in global pharmaceutical market 2015
  • Exhibit 16: Global hypertension drugs market 2015-2020 ($ billions)
  • Exhibit 17: Five forces analysis
  • Exhibit 18: Global hypertension drugs market segmentation by type 2015
  • Exhibit 19: Global systemic hypertension drugs market 2015-2020 ($ billions)
  • Exhibit 20: Global PAH drugs market 2015-2020 ($ billions)
  • Exhibit 21: Segmentation of global hypertension drugs market by drug class
  • Exhibit 22: Global systemic hypertension drugs market share by drug class 2015
  • Exhibit 23: Global PAH drugs market share by drug class 2015
  • Exhibit 24: Segmentation of global hypertension drugs market based on geography 2015
  • Exhibit 25: Hypertension drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 26: Percentage share of hypertension drugs market by geography 2015-2020
  • Exhibit 27: Hypertension drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 28: Hypertension drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 29: Hypertension drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 30: Global hypertension drugs market: YoY growth rate and revenue based on geography 2015-2020
  • Exhibit 31: Population aged 60 years and over: World, developed, and developing regions ($ millions)
  • Exhibit 32: Impact of drivers
  • Exhibit 33: Impact of drivers and challenges
  • Exhibit 34: Sales of major drugs in global hypertension drugs market 2014 ($ billions)
  • Exhibit 35: Novartis: YoY growth rate and revenue of Diovan 2012-2015 ($ billions)
  • Exhibit 36: Novartis: YoY growth rate and revenue of Exforge 2012-2015 ($ billions)
  • Exhibit 37: Novartis: Key takeaways
  • Exhibit 38: Daiichi Sankyo: YoY growth rate and revenue of Olmetec in Japan 2012-2014 ($ millions)
  • Exhibit 39: Daiichi Sankyo: YoY growth rate and revenue of Olmetec/Olmetec Plus in Europe 2012-2014 ($ millions)
  • Exhibit 40: Daiichi Sankyo: YoY growth rate and revenue of Rezaltas in Japan 2012-2014 ($ millions)
  • Exhibit 41: Daiichi Sankyo: YoY growth rate and revenue of Artist in Japan 2012-2014 ($ millions)
  • Exhibit 42: Daiichi Sankyo: YoY growth rate and revenue of Benicar/Benicar HCT in US 2012-2014 ($ millions)
  • Exhibit 43: Daiichi Sankyo: YoY growth rate and revenue of AZOR in US 2012-2014 ($ millions)
  • Exhibit 44: Daiichi Sankyo: YoY growth rate and revenue of TRIBENZOR in US 2012-2014 ($ millions)
  • Exhibit 45: Daiichi Sankyo: YoY growth rate and revenue of Sevikar in Europe 2012-2014 ($ millions)
  • Exhibit 46: Daiichi Sankyo: YoY growth rate and revenue of Sevikar HCT in Europe 2012-2014 ($ millions)
  • Exhibit 47: Daiichi Sankyo: Key takeaways
  • Exhibit 48: Actelion Pharmaceuticals: YoY growth rate and revenue of Tracleer 2011-2014 ($ billions)
  • Exhibit 49: Actelion Pharmaceuticals: YoY revenue of Opsumit 2013 and 2014 ($ millions)
  • Exhibit 50: Actelion Pharmaceuticals: YoY growth rate and revenue of Ventavis 2011-2014 ($ millions)
  • Exhibit 51: Actelion Pharmaceuticals: YoY growth rate and revenue of Veletri 2011-2014 ($ millions)
  • Exhibit 52: Actelion Pharmaceuticals: Key takeaways
  • Exhibit 53: Boehringer Ingelheim: YoY growth rate and revenue of Micardis 2012-2014 ($ millions)
  • Exhibit 54: Boehringer Ingelheim: Key takeaways
  • Exhibit 55: Sanofi: YoY growth rate and revenue of Aprovel 2012-2014 ($ millions)
  • Exhibit 56: Sanofi: YoY growth rate and revenue of Tritace 2012-2014 ($ millions)
  • Exhibit 57: Sanofi: YoY growth rate and revenue of Lasix 2012-2014 ($ millions)
  • Exhibit 58: Sanofi: Key takeaways
  • Exhibit 59: AstraZeneca: Business segmentation by revenue 2015
  • Exhibit 60: AstraZeneca: YoY growth rate and revenue of Seloken/Toprol 2013-2015 ($ millions)
  • Exhibit 61: AstraZeneca: YoY growth rate and revenue of Atacand 2013-2015 ($ millions)
  • Exhibit 62: AstraZeneca: YoY growth rate and revenue of Tenormin 2012-2014 ($ millions)
  • Exhibit 63: AstraZeneca: Key takeaways
Back to Top